{
  "id": "61f5f1ef882a024a10000015",
  "type": "list",
  "question": "Which diseases can be treated with Itepekimab?",
  "ideal_answer": "Itepekimab, a monoclonal antibody targeting IL-33, demonstrated clinical activity in asthma, with potential in chronic obstructive pulmonary disease (COPD).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34302758",
    "http://www.ncbi.nlm.nih.gov/pubmed/34706171",
    "http://www.ncbi.nlm.nih.gov/pubmed/34523807"
  ],
  "snippets": [
    {
      "text": "Itepekimab, a monoclonal antibody targeting IL-33, demonstrated clinical activity in asthma, with potential in chronic obstructive pulmonary disease (COPD). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34302758",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "On the basis of the strong association of IL-33 pathway genes with pulmonary diseases like asthma and COPD, we conducted this phase 2a trial to assess the safety and efficacy of itepekimab in patients with moderate-to-severe COPD on a stable regimen of triple-inhaled or double-inhaled background maintenance therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34302758",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34302758",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "INTERPRETATION: The primary endpoint in the overall population was not met, subgroup analysis showed that itepekimab reduced exacerbation rate and improved lung function in former smokers with COPD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34302758",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34706171",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSIONS: Interleukin-33 blockade with itepekimab led to a lower incidence of events indicating a loss of asthma control than placebo and improved lung function in patients with moderate-to-severe asthma. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34706171",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first-in-human and first-in-patient trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34523807",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Itepekimab, a monoclonal antibody targeting IL-33, demonstrated clinical activity in asthma, with potential in chronic obstructive pulmonary disease (COPD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34302758",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ptibility. Itepekimab, a monoclonal antibody targeting IL-33, demonstrated clinical activity in asthma, with potential in chronic obstructive pulmonary diseas",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34302758",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34706171",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "with the combination therapy. Itepekimab treatment improved asthma control and quality of life, as compared with placebo, and led to a greater reduction in th",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34706171",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " [95% CI 0\u00b701-0\u00b710], p=0\u00b7024). When analysis was restricted to former smokers, treatment with itepekimab was associated with nominally significant reductions in acute exacerbations of COPD (RR 0\u00b758 [95% CI 0\u00b739-0\u00b785], p=0\u00b70061) and FEV1 improvement (least squares mean difference 0\u00b709 L [0\u00b702-0\u00b715], p",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34302758",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "racterised for COPD. We then did a double-blind, phase 2a trial comparing itepekimab with placebo in patients with moderate-to-severe COPD despite standard therapy, at 83 study si",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34302758",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "asthma, chronic obstructive pulmonary disease"
}